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Abstract
An individualized dose rule recommends a dose level within a continuous safe dose
range based on patient level information such as physical conditions, genetic factors
and medication histories. Traditionally, personalized dose finding process requires re-
peating clinical visits of the patient and frequent adjustments of the dosage. Thus
the patient is constantly exposed to the risk of underdosing and overdosing during the
process. Statistical methods for finding an optimal individualized dose rule can lower
the costs and risks for patients. In this article, we propose a kernel assisted learning
method for estimating the optimal individualized dose rule. The proposed methodology
can also be applied to all other continuous decision-making problems. Advantages of
the proposed method include robustness to model misspecification and capability of
providing statistical inference for the estimated parameters. In the simulation studies,
we show that this method is capable of identifying the optimal individualized dose rule
and produces favorable expected outcomes in the population. Finally, we illustrate our
approach using data from a warfarin dosing study for thrombosis patients.
Keywords— Individualized dose rules, Kernel estimation, Personalized medicine, Value func-
tion.
1 Introduction
Statistical methods are increasingly popular for optimizing drug doses in clinical trials. A typical
dose-finding study is conducted by a double-blind randomized trial where each patient is randomly
assigned a dose among a few safe dose levels for a candidate drug (Chevret, 2006). At the end of the
trial, a single dose leading to the best average treatment effect is determined as a recommendation
for future patients. However, different patients might respond differently to the same dose of a drug
due to their differences in physical conditions, genetic factors, environmental factors and medication
histories. Taking these differences into consideration when making dose decisions is essential for
achieving better treatment results.
Recently, there has been a growing interest in personalized treatments optimization. However,
most of the methods are restricted to a finite number of treatment options. In particular, people
∗Email: lzhu12@ncsu.edu
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are interested in finding individualized treatment rules, which output a treatment option within
a finite number of available treatments based on patient level information. Such treatment rules
can thus be used to guide treatment decisions aiming to maximize the expected clinical outcome
of interest, also known as the expected reward or value. An optimal treatment rule is defined
to be the one that maximizes the value function in the population among a class of treatment
rules. Various statistical learning methods have been proposed to infer optimal individualized
treatment rules using data from randomized trials or observational studies. Existing methods
include model-based approaches, such as the Q-learning (Watkins and Dayan, 1992; Zhao et al.,
2009; Qian and Murphy, 2011) and A-learning (Murphy, 2003; Robins, 2004; Henderson et al., 2010;
Liang et al., 2018; Shi et al., 2018), direct value search methods by maximizing a nonparametric
estimator of the value function (Zhang et al., 012a,b; Zhao et al., 2012; Fan et al., 2017; Shi et al.,
2019; Zhou et al., 2019), and other semi-parametric methods (Song et al., 2017; Kang et al., 2018;
Xiao et al., 2019).
The above methods, however, are not directly applicable when the number of possible treatment
levels is large. Let us illustrate with warfarin, which is an anticoagulant drug commonly used for the
prevention of thrombosis and thromboembolism. Establishing the appropriate dosage for warfarin
is known to be a difficult problem because the optimal dosage can vary by a factor of 10 among
patients, from 10mg to 100mg per week (Consortium, 2009). Incorrect dosages contribute largely
to the adverse effects of warfarin usage. Underdosing will fail to alleviate symptoms in patients
and overdosing will lead to catastrophic bleeding. In this case, an individualized dose rule, where a
dose level is suggested within a continuous safe dose range according to each individual’s physical
conditions, would be better at tailoring to patient heterogeneity in drug response. Several methods
have been proposed for finding optimal individualized dose rules. One way of extending existing
methods to the continuous dose case is to discretize the dose levels. Laber and Zhao (2015) proposed
a tree-based method and turned the problem into a classification problem by dividing patients into
subgroups and assigning a single dose to each subgroup. Chen et al. (2018) extended the outcome
weighted learning method (Zhao et al., 2012) from binary treatment settings to ordinal treatment
settings. However, in cases where patient responses are sensitive to dose changes, a discretized dose
rule with a small number of levels will fail to provide dose recommendations leading to optimal
clinical results. On the other hand, a discretized dose rule with a large number of levels may result
in limited observations within each subgroup, and thus may be at risk of overfitting.
Alternatively, Rich et al. (2014) extended the Q-learning method by modeling the interactions
between the dose level and covariates with both linear and quadratic terms in doses. However, such
a parametric approach is sensitive to model misspecification and the estimated individualized dose
rule might be far away from the true optimal dose rule. In addition, it cannot be guaranteed that
the estimated optimal dose falls into the safe dose range. More recently, Chen et al. (2016) extended
the outcome weighted learning method proposed by Zhao et al. (2012) and transformed the dose-
finding problem into a weighted regression with individual rewards as weights. The optimal dose
rule is then obtained by optimizing a non-convex loss function. This method is robust to model
misspecification and has appealing computational properties, however, the associated statistical
inference for the estimated dose rule is challenging to determine. In this article we propose a
kernel assisted learning method to infer the optimal individualized dose rule in a manner which
enables statistical inference. Our proposed method can be viewed as a direct value search method.
Specifically, we first estimate the value function with a kernel based estimator. Then we search
for the optimal individualized dose rule within a prespecified class of rules where the suggested
doses always lie in the safe dose range. The proposed method is robust to model misspecification
and is applicable to data from both randomized trials and observational studies. We establish the
consistency and asymptotic normality of the estimated parameters in the obtained optimal dose rule.
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In particular, the asymptotic covariance of the estimators is derived based on nontrivial calculations
of the expectation of a U-statistic.
The remainder of the article is organized as follows. In Section 2, we present the problem setting
and our proposed method. The theoretical results of the estimated parameters are established in
Section 3. In Section 4, we demonstrate the empirical performance of the proposed method via
simulations. In Section 5, the proposed method is further illustrated with an application to a
warfarin study. Some discussions and conclusions are given in Section 6. Proofs of the theoretical
results are provided in the appendix.
2 Method
2.1 Problem Setting
The observed data consist of n independent and identically distributed observations {(Xi, Ai,
Yi)}
n
i=1, where Xi ∈ X is a d dimensional vector of covariates for the ith patient, Ai ∈ A is
the dose assigned to the patient with A being the safe dose range, and Yi ∈ R is the outcome of
interest. Without loss of generality, we assume that larger Y means better outcome. Let π(X)
denote an individualized dose rule, which is a deterministic mapping function from X to A. To
define the value function of an individualized dose rule, we use the potential outcome framework
(Rubin, 1978). Specifically, let Y ∗(a) be the potential outcome that would be observed when a dose
level a ∈ A is given. Define the value function as the expected potential outcome in the population
if everyone follows the dose rule π, i.e. V (π) = E[Y ∗{π(X)}]. The optimal individualized dose rule
is defined as πopt = argmax V (π).
In order to estimate the value function from the observed data, we need to make the following
three assumptions similar to those adopted in the causal inference literature (Robins, 2004). First,
we assume Y =
∫
A δ(A = a)Y
∗(a)da, where δ(·) is the Dirac delta function. This corresponds to
the stable unit treatment value assumption (also known as the consistency assumption). It assumes
that the observed outcome is the same as the potential outcome had the dosage given to the patient
be the actual dose. This assumption also implies that there is no interference among patients.
Second, we assume that the potential outcomes {Y ∗(a) : a ∈ A} are conditionally independent of
A given X, which is also known as the no unmeasured confounders assumption. Third, we assume
that there exists a c > 0 such that p(A = a|X = x) ≥ c for all a ∈ A, x ∈ X , where p(a|x) is the
conditional density of A = a given X = x. This is a generalization of the positivity assumption
for continuous dosing. Under these assumptions, we can show that V (π) can be estimated with the
observed data:
V (π) = E[Y ∗(π(X))] = EX [E{Y
∗(π(X))|X}]
= EX [E{Y
∗(π(X))|A = π(X),X}] = EX [E{Y |A = π(X),X}].
The second equation above is based on the basic property of conditional densities. The third
equation above is valid because of the no unmeasured confounder assumption. The fourth equation
is based on the consistency assumption. The positivity assumption ensures that the right side of
the last equation can be estimated empirically. In the next section, we will propose a consistent
estimator for V (π) based on kernel smoothing.
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2.2 Method
To estimate the optimal IDR, we first estimate V (π) with a kernel based estimator Vˆ (π) and then
estimate πopt by directly maximizing the estimated value function Vˆ (π). We search for the optimal
individualized dose rule within a class of dose rules of the form: πβ(x) = π(x;β) ∈ G, where
G = {g(βTx), β ∈ Rd}, and g : R → A is a predefined link function to ensure that the suggested
dosage is within the safe dose range. Thus πˆopt = argmaxpi∈G Vˆ (π).
Notice that πˆopt is an estimator of the optimal IDR within G: πoptβ = argmaxpi∈G V (π) = πβ∗ ,
where β∗ = argmaxβ V (πβ). If the true optimal IDR lies in G, then the proposed π
opt
β (X) = π
opt.
To see this more clearly, we illustrate with a toy example. If the true model for E(Y |A,X) takes the
form: E(Y |A,X) = µ˜(X) +Q{A− g(β˜TX)}H(X), where µ˜(X) is an unspecified baseline function,
H(X) is a non-negative function and Q(·) is a unimodal function which is maximized at 0, then
E(Y | A,X) is maximized at dose level A = g(β˜Tx) for patients with covariates X = x. Thus, the
true optimal individualized dose rule is:
πopt(X) = argmax
pi
V (π)
= argmax
pi
EX
[
E
{
Y | A = π(X),X
}]
= argmax
pi
EX
[
µ˜(X) +Q
{
π(X) − g(β˜TX)
}
H(X)
]
= argmax
pi
EX
[
Q
{
π(X) − g(β˜TX)
}
H(X)
]
= g(β˜TX) ∈ G.
The last equation above is true because Q{π(X)− g(β˜TX)}H(X) is maximized at g(β˜TX) for each
X ∈ X . If a unique maximizer of V (πβ) exists, then
β∗ = argmax
β
V (πβ)
= argmax
β
EX
[
Q
{
g(βTX)− g(β˜TX)
}
H(X)
]
= β˜.
Therefore, πoptβ = g(β
∗TX) = πopt. Notice that if, πopt =/∈ G, then πoptβ 6= π
opt. However, πoptβ is
still of interest as long as the form of G is flexible enough, because it maximizes the value function
among this set of treatment rules.β∗ can be estimated using βˆ = argmax Vˆ (πβ), and the optimal
IDR within G can be thus estimated with πˆoptβ = π(X; βˆ). Notice that we do not need any model
assumption on the form of the conditional expectation E(Y |A,X) to apply this method.
Next, we propose a kernel based estimator for the value function. Let
M(β) = V
(
πβ
)
=
∫
x∈X
m{x, g(βT x)}f(x)dx,
where m(x, a) = E(Y | X = x,A = a) and f(x) is the marginal density of X. Thus, β∗ =
argmaxβM(β). The functionm{x, g(β
T x)} is estimated using the Nadaraya-Watson method given:
mˆ{x, g(βT x)} =
1
n
∑n
i=1 Yi
1
hdx
Kd(
x−Xi
hx
) 1haK
{g(βT x)−Ai
ha
}
1
n
∑n
i=1
1
hdx
Kd(
x−Xi
hx
) 1haK
{g(βT x)−Ai
ha
} ,
where K(·) is a univariate kernel function and Kd(·) is a d dimensional kernel function. Here, hx
and ha are bandwidths that go to 0 as n → ∞. Note that for simplicity of notification, we use
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the same bandwidth for all dimensions of X here. In practice, we can use different bandwidths
for different dimensions of X to increase the efficiency of the estimation. Moreover, the marginal
density of X is estimated by fˆ(x) = (1/n)
∑n
i=1Kd{(x−Xi)/hx}/h
d
x. The estimated value function
can thus be written as:
Mn(β) =
∫
x
[ 1
n
∑n
i=1 Yi
1
hdx
Kd(
x−Xi
hx
) 1haK
{g(βT x)−Ai
ha
}
1
n
∑n
i=1
1
hdx
Kd(
x−Xi
hx
) 1haK
{g(βT x)−Ai
ha
} ][ 1
n
n∑
i=1
1
hdx
Kd(
x−Xi
hx
)
]
dx.
Then β∗ is estimated with βˆn = argmaxβ∈ΘMn
(
β
)
, where Θ is a compact subset of Rd containing
β∗.
2.3 Computational Details
To implement the proposed method, the R package optimr() is used for optimization of the objective
function. The integral in Mn(β) is estimated by taking the average of q grid points in the covariate
space. In our implementation, we chose q = 3000. In order to find the global maximizer of Mn(β),
we start optimization from d different initial points {(1, 0, ..., 0), (0, 1, 0, ..., 0), ..., (0, ..., 0, 1)} and
choose the one that leads to the maximal objective function value. Denote the maximizer as βˆn.
When there is only one continuous covariate included, following the theoretical rate of the bandwidth
parameters, the bandwidths are chosen as hx = Cxsd(X)n
−1/4.5, ha = Casd(A)n
−1/4.5, where Cx
and Ca are constants between 0.5 and 3.5.
When the covariates consist of both continuous variables and categorical variables, the cat-
egorical variables are stratified for estimation of the value function. Specifically, assume that
X = (XT1 ,X
T
2 )
T ∈ X , where X1 ∈ C is a d1 dimensional vector of continuous variables and X2 ∈ D
is a d2 dimensional vector of categorical variables. The form of Mn(β) then becomes:
Mn(β) =
∑
x2∈D
∫
x1∈C
[ 1
n
∑n
i=1 YiK˜(x,Xi)
1
ha
K
{g(βTX)−Ai
ha
}
1
n
∑n
i=1 K˜(x,Xi)
1
ha
K
{g(βTX)−Ai
ha
} ]{ 1
n
n∑
i=1
K˜(x,Xi)
}
dx1,
where x = (xT1 , x
T
2 )
T , Xi = (X
T
i1,X
T
i2)
T ,
K˜(x,Xi) = (1/h
d1
x )Kd1{(x1 −Xi1)/hx}I(Xi2 = x2).
The R code for the proposed method is available at: https://github.com/lz2379/Kernel_Assisted_Learning
3 Theoretical Results
In this section, we establish the asymptotic properties of βˆn. To prove these results, we need to make
the following assumptions. In the following equations, f˙(x), f¨(x) and
...
f (x) denote the first, second
and third derivatives of the function f with respect to x; κ0,2 =
∫
R
K2(v)dv and κ˙0,2 =
∫
R
K˙2(v)dv.
Assumption 1. 1 Assume that K˙(v), K¨(v) and
...
K(v) exist for v ∈ V, where V is a subset of R.
For h → 0+ as n → ∞ and constants l,u such that l < 0 < u,
∫
[l/h,u/h]∩V K(v)dv = 1 − O(h
2),∫
[l/h,u/h]∩V vK(v)dv = O(h),
∫
[l/h,u/h]∩V K˙(v)dv = O(h
3),
∫
[l/h,u/h]∩V −vK˙(v)dv = 1 − O(h
2),∫
[l/h,u/h]∩V K
2(v)dv = κ0,2−O(h
2),
∫
[l/h,u/h]∩V K˙
2(v)dv = κ˙0,2−O(h
2),
∫
[l/h,u/h]∩V K¨(v)dv = O(h
4),∫
[l/h,u/h]∩V vK¨(v)dv = O(h
3),
∫
[l/h,u/h]∩V v
2K¨(v)dv = 2 − O(h2),
∫
[l/h,u/h]∩V
...
K(v)dv = O(h3),∫
[l/h,u/h]∩V v
...
K(v)dv = O(h2),
∫
[l/h,u/h]∩V v
2
...
K(v)dv = O(h),
∫
[l/h,u/h]∩V v
3
...
K(v)dv = O(1).
Assumption 2. The function M(β) = V (πβ) has a unique maximizer β
∗.
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Assumption 3. The function m(x, a) is uniformly bounded. The joint density function of X and
A, f(x, a), is uniformly bounded away from 0. In addition, the first, second, third and fourth order
derivatives of m(x, a) and f(x, a) with respect to x and a exist and are uniformly bounded almost
everywhere.
Assumption 4. The covariate X has bounded first, second and third moments.
Assumption 5. The function g(·) is thrice differentiable almost everywhere and the corresponding
derivatives, g˙((·), g¨(·),
...
g (·) are bounded almost everywhere.
Assumption 1 can be satisfied by most commonly used kernel functions such as the Gaussian
kernel function and all sufficiently smooth bounded kernel functions. Assumption 2 is an identifi-
ability condition for β∗. Assumptions 3–5 ensure the existence of the limit of the expectation of
Mn(β) and the existence of the covariance matrix of the limiting distribution. In the following two
theorems, we establish the consistency and asymptotic normality of βˆn, respectively.
Theorem 1. Under assumptions 1–3, for hx, ha satisfying
nh2dx h
2
a →∞ as n→∞, we have supβ∈Θ |Mn(β)−M(β)| converge in probability to 0, where Θ is
a compact region containing β∗. Thus, βˆn = argmaxβ∈ΘMn(β) converge in probability to β
∗.
Theorem 2. Under assumptions 1–5, for hx, ha satisfying
nh2dx h
2
a →∞ and nh
d
xh
3
a →∞ as n→∞, we have
(nhdxh
3
a)
1/2(βˆn − β
∗)→ N
{
0,D(β∗)−1ΣS(β
∗)D−1(β∗)
}
in distribution as n→∞, where
D(β∗) =
∫
x
[
maa
{
x, g(βTx)
}
g˙2(βTx) +ma
{
x, g(βT x)
}
g¨(βTx)
]
f(x)xxTdx,
ΣS(β
∗) =
∫
x
[
g˙2(βTx)xxTκ0,2κ˙0,2f
2(x)
][m2{x, g(xTβ)}−m2{x, g(xTβ)}
f
{
x, g(xTβ)
} ]dx,
and ma(x, a) = ∂m(x, a)/∂a, maa(x, a) = ∂
2m(x, a)/∂a2, m2(x, a) = E(Y
2 | X = x,A = a).
Proofs of the above theorems are based on theory for kernel density estimators (Schuster et al.,
1969) and M-estimation (Kosorok, 2008). Details of proofs are given in the appendix. Note that
the convergence rate is slower then n1/2 due to the kernel estimation of the value function.
4 Simulation Studies
In this section, we conduct some simulations to show the capability of our proposed method in
identifying the optimal individualized dose rule. We first simulate some simple settings with only
one covariate. X is generated randomly from the standard normal distribution. A is generated from
the uniform distribution on [0, 1]. We generate X and A independently to mimic a randomized dose
trial where a random dose from the safe dose range is assigned to each patient. The optimal dose rule
is πopt(X) = g(β˜0+ β˜1X), where g(s) = 1/{1+exp(−s)}. Y is generated from a normal distribution
with mean m(A,X) and standard deviation 0.5, where m(A,X) = µ˜(X) − 10{A − πopt(X)}2. We
use two different baseline functions for µ˜(X) and two different sets of (β˜0, β˜1) as shown in Table 1.
The sample sizes are n = 400 and n = 800 and each setting is replicated 500 times.
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Table 1: Summary of simulation settings
No baseline With baseline
µ˜(X) = 0 µ˜(X) = 1 + 0.5 cos(2piX)
β˜0 = 0, β˜1 = 0.5 Setting 1 Setting 3
β˜0 = 0, β˜1 = 1 Setting 2 Setting 4
The average bias and the standard deviation of the estimated parameters from 500 simulations
are summarized in the first half of Table 2. The estimated parameters were close to the true pa-
rameters. The third column shows the average of the standard errors estimated with the covariance
function formula derived in Theorem 2 (see appendix for details). 95% confidence intervals were
calculated with the estimated standard errors. The coverage probabilities are shown in the table.
From the result, we can see that the bias and standard deviation of the estimated parameters de-
creased with larger sample sizes. The coverage probabilities of the confidence intervals were close
to 95%, supporting the convergence results given in Section 3.
We also study the performance of our method when the training data are from observational
studies, where the doses given to the patients may depend on the covariates X. The simulation
settings are the same as settings 1–4 except that A is generated from the distribution beta
{
2 exp(β˜0+
β˜1X), 2
}
. The results are summarized in the second half of Table 2. The proposed method was
still capable of giving good estimates of the parameters and the coverage of the confidence intervals
were close to 95%. These simulation implies that the proposed method performs well with data
from both randomized trials and observational studies.
Under settings 1–4, we compare our method with linear based O-learning (LOL) and kernel
based O-learning (KOL) proposed in Chen et al. (2016) and a discretized dose rule estimated us-
ing Q-learning. For discretized Q-learning, we divide the safe dose range into 10 equally spaced
intervals: A = A1 ∪ · · · ∪ A10 and create an indicator variable for each of the dose intervals
I = (I1, I2, . . . , I10), where Ij = I(A ∈ Aj), j = 1, . . . , 10. The covariates included in the re-
gression models are (X,X2, I, IX, IX2). To this end, an optimal dose range is selected for each
individual and the middle point of the selected interval is suggested to the patient. The results from
500 replicates are summarized in Table 3. Each column is the average value function of the dose rule
estimated by the corresponding method. The value function is evaluated at a testing dataset. The
numbers in the parentheses are the standard deviation of the estimated value functions. From Table
3, we see that the proposed method performed the best under most settings. In the simulation for
observational studies, O-learning performed the best when the sample size was small. However, the
proposed method performed comparatively well and performed better as the sample size increased.
The discretized Q-learning method did not provide a good dose suggestion in this case.
5 Warfarin Data Analysis
Warfarin is a widely used anticoagulant for prevention of thrombosis and thromboembolism. Al-
though highly efficacious, dosing for warfarin is known to be challenging because of the narrow
therapeutic index and the large variability among patients (Johnson et al., 2011). Overdosing of
warfarin leads to bleeding and underdosing diminishes the efficacy of the medication. The inter-
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Table 2: Simulation results from 500 replicates for randomized trials and observational stud-
ies.
Randomized trials
βˆn,0 βˆn,1
n Bias∗ SD∗ SE∗ CP Bias∗ SD∗ SE∗ CP
S1 400 2.5 46.6 47.5 95.6 -17.3 53.5 54.5 92.8
800 2.4 33.7 33.4 95.8 -19.5 37.3 38.5 90.2
S2 400 2.1 52.2 54.4 95.6 38.9 91.0 93.7 94.6
800 1.5 39.1 38.1 93.8 33.0 63.0 65.9 95.8
S3 400 2.7 54.1 55.7 95.2 -20.4 64.5 64.1 90.8
800 1.6 38.8 39.3 95.0 -18.9 43.7 45.4 92.0
S4 400 2.4 61.8 63.4 95.4 39.4 103.5 111.2 96.2
800 -1.5 44.4 44.3 94.6 33.6 75.0 77.5 95.6
Observational studies
βˆn,0 βˆn,1
n Bias∗ SD∗ SE∗ CP Bias∗ SD∗ SE∗ CP
S1 400 13.9 80.5 82.4 96.0 32.4 97.7 102.1 94.6
800 8.5 47.3 47.0 94.6 -19.6 56.7 58.2 92.2
S2 400 21.9 83.3 88.1 96.4 7.6 146.4 150.4 95.2
800 17.8 63.4 60.9 93.0 0.6 94.0 103.2 98.2
S3 400 13.4 89.4 90.2 95.6 33.2 109.3 112.3 94.8
800 9.0 53.1 50.6 93.0 -22.8 60.2 63.2 93.4
S4 400 21.6 91.3 97.1 96.2 5.0 165.4 169.3 95.8
800 20.3 71.2 67.6 93.2 2.0 109.0 116.8 97.0
1 Note: * columns are in 10−3 scale
2 Note: SD refers to the standard deviation of the estimated param-
eters from 500 replicates, SE refers to the mean of the estimated
standard errors calculated by our covariance function, CP refers
to the coverage probability of the 95% confidence intervals calcu-
lated using the estimated standard errors.
3 Note: The worst case Monte Carlo standard error for proportions
is 1.3%.
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Table 3: Value estimate V (pˆi) from 500 simulations in settings 1-4
Randomized trials
n DQ LOL KOL KAL
S1 400 -38.1(1.9) -7.7(7.0) -16.5(8.2) -2.7(2.7)
800 -32.7(0.9) -3.9(3.7) -9.3(4.3) -1.9(1.8)
S2 400 -33.9(1.3) -18.1(10.5) -31.7(12.5) -3.3(3.7)
800 -20.0(0.8) -15.6(7.5) -20.4(7.4) -1.9(1.8)
S3 400 -41.6(11.4) -8.5(14.1) -17.2(14.2) -3.7(12.4)
800 -61.2(11.5) -4.3(12.1) -10.0(12.7) -2.4(11.7)
S4 400 -52.5(11.9) -21.3(17.7) -33.3(17.4) -4.2(12.5)
800 -23.3(11.9) -17.8(14.5) -22.4(13.9) -2.4(11.7)
Observational studies
n DQ LOL KOL KAL
S1 400 -29.5(1.2) -7.4(6.3) -15.6(7.7) -8.1(8.0)
800 -24.4(0.9) -5.5(4.3) -10.3(5.3) -3.1(3.1)
S2 400 -16.0(7.6) -14.1(6.6) -21.3(9.7) -8.2(8.3)
800 -32.0(1.1) -12.8(4.7) -12.2(4.5) -4.4(4.4)
S3 400 -29.1(11.6) -8.1(13.5) -11.7(14.6) -9.8(15.7)
800 -34.2(11.8) -6.2(12.4) -11.2(13.3) -3.5(12.0)
S4 400 -83.8(13.8) -14.7(13.0) -20.7(15.8) -10.0(15.8)
800 -34.1(11.3) -13.5(12.1) -11.2(12.3) -5.1(12.2)
1 Note: DQ refers to discretized Q-learning, LOL refers to linear O-
learning, KOL refers to kernel based O-learning, KAL refers to kernel
assisted learning.
2 All columns are in 10−3 scale. For settings 3 and 4, the numbers in the
table are the value estimate V (πˆ)−1 for the purpose of comparison with
the first two settings.
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national normalized ratio (INR) measures the clotting tendency of the blood. An INR between
2–3 is considered to be safe and efficacious for patients. Typically, the warfarin dosage is decided
empirically: an initial dose is given based on the population average, and adjustments are made in
the subsequent weeks while the INR of the patient is being tracked. A stable dose is decided in the
end to achieve an INR of 2–3 (Johnson et al., 2011). The dosing process may take weeks to months,
during which the patient is constantly at risk of bleeding or under-dosing. Therefore, a quantitative
method for warfarin dosing will greatly decrease the time, cost and risks for patients.
The following analysis uses the warfarin dataset collected by Consortium (2009). In the original
paper, a linear regression was used to predict the stable dose using clinical results and pharmacoge-
netic information, including age, weight, height, gender, race, two kinds of medications (Cytochrom
P450 and Amiodarone), and two genotypes (CYP2C9 genotype and VKORC1 genotype). This
prediction method is based on the assumption that the stable doses received by the patients are
optimal. However, later studies showed that the suggested doses by the International Warfarin
Pharmacogenetic Consortium are suboptimal for elderly people, implying that the optimal dose
assumption might not be valid (Chen et al., 2016).
We apply our proposed method to this dataset to estimate the optimal individualized dose rule
for warfarin. Instead of using only the data of the patients with stablized INR, we include all
patients who received weekly doses between 6 mg to 95 mg. The medication information is missing
for half of the observations and is therefore excluded from our analysis. Observations which are
missing in the other variables are removed from the dataset, resulting in a total of 3567 patients.
The outcome variable is defined as Yi = −(INRi − 2.5)
2 for the i-th observation. Stratification
of the categorical variables is needed for the kernel density estimation. In order to ensure that
there are enough observations in each stratified group, we consider only categorical variables that
are distributed comparatively even among different groups. In our analysis, we use three variables:
height, gender and the indicator variable for VKORC1 of type AG. Before we apply the proposed the
method, we normalize all the variables by Xi,j = (Xi,j − X¯j)/sd(Xj), where j = 1, 2, 3, i = 1, . . . , n.
X¯j =
∑n
i=1Xi,j/n and sd(Xj) is the standard deviation of the j-th variable.
The estimation results are shown in Table 4. The p-value is obtained for each of the parameters.
The result implied that the optimal dose for male is higher than the optimal dose for female
given all the other variables being the same. It was also implied that the patients with genotype
VKORC1=AG need higher doses than the patients with VKORC16= AG. We use the same variables
and compare our method with O-learning and the discretized Q-learning method. For the discretized
Q-learning method, we also divide the dose range into 10 equally spaced intervals. The suggested
doses by the three methods are shown in Fig. 2. The result shows a tendency of the discretized
Q-learning to suggest extreme doses, which is not ideal in real application. This might be due to the
fact that the higher dose intervals contain small numbers of observations, and thus the estimated
models are dominated by a few subjects.
To evaluate the estimated dose rules of these methods, we randomly take two thirds of the data
as training data and the rest of the data as testing data. The optimal individualized dose rule
is estimated with the training data. The value function of the suggested individualized dose rule
V (πˆ) is estimated with the average of the Nadaraya Watson estimator for E{Y | X,A = πˆ(X)}
in the testing dataset. The tuning parameters for the Nadaray-Watson estimators are taken as
hx = 1.25sd(X)n
−1/4.5
test and ha = 1.75sd(A)n
−1/4.5
test , where ntest = 1189 is the size of the testing
dataset. The process is repeated 200 times. The distribution of the estimated value of the suggested
dose is shown in Fig. 3. The suggested individualized dose rule with our proposed method lead to
better expected outcomes in the population compared to the other methods. The performance of
the discretized Q-learning method was not stable as shown in the result. However, this result was
only based on the three variables selected, while in reality, the two medications (Cytochrome P450
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Figure 1: Distribution of the variables in the warfarin dataset.
Table 4: Estimated βˆ with warfarin data with kernel assisted learning
Variable Estimated Parameter SE p-value
Intercept -0.463 0.064 0.000
Height -0.263 0.101 0.005
Gender 0.268 0.134 0.023
VKORC1.AG -0.4682 0.094 0.000
enzyme and Amiodarone) and the genotype CYP2C9 are also of significant importance in warfarin
dosing. The computation complexity of our proposed method restricted its capability of handling
higher dimensional problems.
6 Discussion and Conclusion
The proposed kernel assisted learning method for estimating the optimal individualized dose rule
provides the possibility of conducting statistical inference with estimated dose rules, thus providing
insights on the importance of the covariates in the dosing process. In our simulation settings, our
method was capable of identifying the optimal individualized dose rule when the optimal dose rule
was inside the prespecified class of rules. In the warfarin dosing case, based on the three covariates
selected, the suggested dose lead to better expected clinical result compared to the other methods.
Application of the proposed methodology is not limited to optimal dose finding. This method can
also be applied to any scenario where continuous decision making is desired.
The proposed method has several possible extensions. Notice that the form of the prespeci-
fied rule class can be extended to a link function with a nonlinear predictor g{Ψ(X)T β} where
Ψ(·) = {Ψ1(·), ...,Ψc(·)}
T are some prespecified basic spline functions and β ∈ Rc . The accuracy
of the approximated value function might also be improved by extending the multivariate kernel
Kd(x/hx)/hx to |H|
−1/2Kd(H
−1/2x) (Duong and Hazelton, 2005).
One weakness of the proposed method is that the accuracy of the estimated value function is
sensitive to the choice of bandwidth. The kernel density estimator in the denominator of Mn(β)
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(a)
(b)
Figure 2: Empirical distribution of suggested doses of several methods for the walfarin
dataset. In panel (a), the black line is the distribution of the original doses from the dataset.
The green line denotes the result from linear O-learning. The blue line denotes the result
from kernel based O-learning. The red line denotes the result from kernel assisted learning.
Panel (b) is the histogram of the suggested doses using discretized Q-learning.
Figure 3: Empirical distribution of the estimated value function over 200 repetitions for the
warfarin dataset.
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might lead to large bias when the bandwidths are not properly chosen. As the dimension of X
increases, the choice of the bandwidths is nontrivial. The criteria for choosing bandwidths needs to
be studied further.
In the future, we are interested in variable selection when dealing with high dimensional data.
Extensions to multi-stage dose finding problems is also of interest. Personalized Dose Finding is still
a relatively new problem. With the complicated mechanisms of various diseases, there are many
more problems to be tackled in this realm.
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A Proof of Theorem 1
We first prove the uniform convergence of Mn(β) to M(β). For simplicity of notation, let’s define:
mx(x, a) = ∂m(x, a)/∂x, m2x(x, a) = ∂m2(x, a)/∂x, m2a(x, a) = ∂m2(x, a)/∂a. Similarly,
fa(x, a) = ∂fX,A(x, a)/∂a, fx(x, a) = ∂fX,A(x, a)/∂x. We write Mn(β) as
Mn(β) =
∫
x
An(x;β)
Bn(x;β)
Cn(x)dx,
where
An(x;β) =
1
n
n∑
i=1
Yi
1
hqx
Kq(
x−Xi
hx
)
1
ha
K
{g(βTx)−Ai
ha
}
,
Bn(x;β) =
1
n
n∑
i=1
1
hqx
Kq(
x−Xi
hx
)
1
ha
K
{g(βTx)−Ai
ha
}
,
Cn(x) =
1
n
n∑
i=1
1
hqx
Kq(
x−Xi
hx
).
Notice that M(β) can be written as
M(β) =
∫
x
A(x;β)
B(x;β)
C(β)dx,
where A(x;β) = m{x, g(βT x)}fX,A{x, g(β
T x)}, B(x;β) = fX,A{x, g(β
T x)} and C(x) = fX(x).
Thus,
sup
β
∣∣∣Mn(β)−M(β)∣∣∣ = sup
β
∣∣∣ ∫
x
{An(x;β)
Bn(x;β)
Cn(x)−
A(x;β)
B(x;β)
C(x)
}
dx
∣∣∣
≤ sup
β
∣∣∣ ∫
x
{An(x;β)
Bn(x;β)
−
A(x;β)
B(x;β)
}
Cn(x)dx
∣∣∣+ sup
β
∣∣∣ ∫
x
A(x;β)
B(x;β)
{
Cn(x)− C(x)
}
dx
∣∣∣
≤ sup
a,x
∣∣∣A∗n(x, a)
B∗n(x, a)
−
A∗(x, a)
B∗(x, a)
∣∣∣{ ∫
x
Cn(x)dx
}
+ sup
a,x
|m
(
x, a)|
{∫
x
∣∣∣Cn(x)− C(x)∣∣∣dx},
where
A∗n(x, a) =
1
n
n∑
i=1
Yi
1
hqx
Kq(
x−Xi
hx
)
1
ha
K(
a−Ai
ha
),
B∗n(x, a) =
1
n
n∑
i=1
1
hqx
Kq(
x−Xi
hx
)
1
ha
K(
a−Ai
ha
),
and A∗(x, a) = m(x, a)fX,A(x, a), B
∗(x, a) = fX,A(x, a). It is trivial to prove that
∫
xCn(x)dx =∫
x C(x)dx = 1. Thus, under the boundedness of m(x, a), we only need to show that:∫
x
|Cn(x)− C(x)|dx = op(1),
sup
a,x
∣∣∣A∗n(x, a)
B∗n(x, a)
−
A∗(x, a)
B∗(x, a)
∣∣∣→ 0 = op(1).
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To prove the first equation, notice that
∫
x |Cn(x)−C(x)|dx ≤
∫
xCn(x)dx+
∫
xC(x)dx = 2. By the
dominated convergence theorem, it suffices to show the uniform convergence of the kernel density
estimate Cn(x) to C(x), which can be proved according to Schuster (1969).
For the second equation,
sup
a,x
∣∣∣A∗n(x, a)
B∗n(x, a)
−
A∗(x, a)
B∗(x, a)
∣∣∣
= sup
a,x
∣∣∣
{
A∗n(x, a)−A
∗(x, a)
}
B∗(x, a)−A∗(x, a)
{
B∗n(x, a)−B
∗(x, a)
}
B∗n(x, a)B
∗(x, a)
∣∣∣
≤ sup
x,a
∣∣∣A∗n(x, a)−A∗(x, a)
B∗n(x, a)
∣∣∣+ sup
x,a
∣∣∣
{
B∗n(x, a)−B
∗(x, a)
}
A∗(x, a)
B∗(x, a)B∗n(x, a)
∣∣∣.
Under the boundedness of A∗(x, a) and the assumption that fX,A(x, a) is uniformly bounded away
from 0, it suffices to show that supa,x
∣∣A∗n(x, a)−A∗(x, a)∣∣ = op(1), and supa,x ∣∣B∗n(x, a)−B∗(x, a)∣∣ =
op(1).
To prove the uniform convergence of A∗n(x, a), notice that:
sup
a,x
∣∣∣A∗n(x, a)−A∗(x, a)∣∣∣ ≤ sup
a,x
∣∣∣A∗n(x, a)− E{A∗n(x, a)}∣∣∣+ sup
a,x
∣∣∣E{A∗n(x, a)}−A∗(x, a)∣∣∣. (1)
We prove the convergence of the two parts on the right side separately. First we obtain,
E
{
A∗n(x, a)
}
=∫
xi,ai
∫
yi
{
yi
1
hqx
Kq(
x− xi
hx
)
1
ha
K(
a− ai
ha
)
}
fY |X,A(yi|xi, ai)fX,A(xi, ai)dyidxidai
=
∫
xi,ai
{
m(xi, ai)
1
hqx
Kq(
x− xi
hx
)
1
ha
K(
a− ai
ha
)
}
fX,A(xi, ai)dxidai
=
∫
u
∫ a/ha
v=(a−1)/ha
m(x− uhx, a− vha)Kq(u)K(v)fX,A(x− uhx, a− vha)dvdu
=
∫
u
∫ a/ha
v=(a−1)/ha
{
m
(
x, a
)
− uhxmx
(
x, a
)
− vhama
(
x, a
)
+O(h2x) +O(hxha) +O(h
2
a)
}
K(u)K(v)
{
fX,A
(
x, a
)
− uhxfx
(
x, a
)
− vhafa
(
x, a
)
+O(h2x) +O(hxha) +O(h
2
a)
}
dvdu
= m
(
x, a
)
fX,A
(
x, a
)
+O(h2x) +O(h
2
a)
= A∗(x, a) +O(h2x) +O(h
2
a),
where the third equality is achieved by letting u = (x − X)/hx and v = {g(β
T x) − A}/ha. The
fourth equation is from Taylor expansion and the fifth equation is based on Assumption (A1) that∫
u uKq(u)du = 0,
∫ g(β′x)/ha
{g(β′x)−1}/ha
K(v)dv = 1 − O(h2a) and
∫ g(β′x)/ha
{g(β′x)−1}/ha
vK(v)dv = O(ha). By the
assumption of uniform boundedness of the second order derivatives of m(x, a) and fX,A(x, a), we
have supx,a |E
{
A∗n(x, a)
}
−A∗(x, a)| → 0.
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Then we prove the convergence of the first part of Equation (1):
sup
x,a
∣∣∣A∗n(x, a)− E{A∗n(x, a)}∣∣∣
=
1
hqxha
sup
x,a
∣∣∣ ∫
X,A
m(X,A)Kq(
x−X
hx
)K(
a−A
ha
)d
{
Fn(X,A) − F (X,A)
}∣∣∣
=
1
hqxha
sup
x,a
∣∣∣∣∣
[{
Fn(x, a) − F (x, a)
}
m(X,A)Kq(
x−X
hx
)K(
a−A
ha
)
]∞
−∞
−
∫
X,A
{
Fn(x, a) − F (x, a)
}
d
{
m(X,A)Kq(
x−X
hx
)K(
a−A
ha
)
}∣∣∣∣∣
≤
C3
hqxha
sup
x,a
∣∣∣Fn(x, a) − F (x, a)∣∣∣,
where C3 is a constant, F (X,A) is the cumulative joint distribution of X and A and Fn(x, a) =
{
∑n
i=1 I(Xi ≤ x,Ai ≤ a)}/n. Here Xi ≤ x means that each term of Xi is less than or equal to
the corresponding term of x. The last inequality can be obtained by the boundedness of m(x, a),
Kq(u) and K(v). By Lemma 2.1 of Schuster (1969) we know that there exists a universal constant
C4 such that for any n > 0, ǫn > 0, PF
{
supx,a
∣∣Fn(x, a) − F (x, a)∣∣ > ǫ} ≤ C4 exp(−2nǫ2). For n
sufficiently large:
P
{
sup
x,a
∣∣A∗n(x, a) −A∗(x, a)∣∣ > ǫ} ≤ P{ sup
x,a
∣∣∣A∗n(x, a)− E{A∗n(x, a)}∣∣∣ > ǫ2
}
≤ P
{
sup
x,a
∣∣Fn(x, a)− F (x, a)∣∣ > hqxhaǫ
2C3
}
≤ C4 exp
(
− 2n
h2qx h2aǫ
2
C23
)
.
If nh2qx h2a → ∞ then P
{
supx,a
∣∣A∗n(x, a) − A∗(x, a)∣∣} → 0. Thus the uniform convergence of
A∗n(x, a) is proved. The uniform convergence of B
∗
n(x, a) can be proved similarly. Thus, we can
obtain supβ∈Θ
∣∣Mn(x;β)−M(x;β)∣∣ p−→ 0. By Theorem 2.10 of Kosorok (2008), we now obtain that
βˆn
p
−→ β∗.
B Proof of Theorem 2
Since βˆn and β
∗ are maximizers of Mn(β) and M(β), they are solutions of Sn(β) = 0 and S(β) = 0,
where, S(β) = ∂M(β)/∂β and Sn(β) = ∂Mn(β)/∂β. By Taylor expansion, we have
0 = Sn(βˆn) = Sn(β
∗) +Dn(β
∗)(βˆn − β
∗) +
1
2
(βˆn − β
∗)T
∂2
∂β∂βT
Sn(β˜)(βˆn − β
∗)
= Sn(β
∗) +
{
Dn(β
∗) +
1
2
(βˆn − β
∗)T
∂2
∂β∂βT
Sn(β˜)
}
(βˆn − β
∗),
where β˜ is on the line segment connecting βˆn and β
∗, Dn(β) = ∂
2Mn(β)/(∂β∂β
T ), D(β) =
∂2M(β)/(∂β∂βT ). To prove the weak convergence of βˆn, we can first prove that:
(nhqxh
3
a)
1/2
{
Sn(β
∗)− S(β∗)
}
→ N
{
0,ΣS(β
∗)
}
, (2)
in distribution as n→∞,
Dn(β
∗)−D(β∗) = op(1), (3)
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12
(βˆn − β
∗)T
∂2
∂β∂βT
Sn(β˜) = op(1). (4)
Then we obtain:
(nhqxh
3
a)
1/2(βˆn − β
∗) = −
{
Dn(β
∗) +
1
2
(βˆn − β
∗)T
∂2
∂β∂βT
Sn(β
∗)
}
(nhqxh
3
a)
1/2Sn(β
∗)
→ N
{
0,D(β∗)−1ΣS(β
∗)D(β∗)−1
}
in distribution as n→∞.
B.1 Proof of Equation 2
To prove Equation 2, we first write Sn(β) as:
Sn(β) =
∂Mn(β)
∂β
=
∫
x
A˜n(x;β)Bn(x;β) −An(x;β)B˜n(x;β)
Bn(x;β)2
Cn(x)dx,
where
A˜n(x;β) =
∂
∂β
An(x;β) =
1
n
n∑
i=1
Yi
1
hqx
Kq(
x−Xi
hx
)
1
h2a
K˙
{g(βTx)−Ai
ha
}
g˙(βTx)x,
B˜n(x;β) =
∂
∂β
Bn(x;β) =
1
n
n∑
i=1
1
hqx
Kq(
x−Xi
hx
)
1
h2a
K˙
{g(βT x)−Ai
ha
}
g˙(βTx)x.
Since Sn(β) is of the integration form, to calculate the limiting distribution of Sn, we can first
calculate the limiting distribution of the part inside the integral for a fixed x.
Let the parts inside the integral of Sn(β) and S(β) be:
Gn(x;β) =
A˜n(x;β)Bn(x;β)−An(x;β)B˜n(x;β)
Bn(x;β)2
Cn(x),
G(x;β) =
A˜(x;β)B(x;β) −A(x;β)B˜(x;β)
B2(x;β)
C(x),
where A˜(x;β) =
[
m
{
x, g(βTx)
}
fa
{
x, g(βT x)
}
+ma
{
x, g(βTx)
}
fX,A
{
x, g(βT x)
}]
g˙(βTx)x and
B˜(x;β) = fa{x, g
(
βTx)
}
.
To prove the limit distribution of Gn(β)−G(β), we need the following lemma:
Lemma 3. If {An}
∞
n=1 and {Bn}
∞
n=1 are two sequences of random variables and cn(An − A) →
N(0,ΣA) in distribution and dn(Bn −B)→ N(0,ΣB) in distribution, where cn/dn → 0 as n→∞.
Then:
cn(AnBn −AB) = cn(An −A)B + op(1).
Proof. Notice that: cn(AnBn −AB) = (cn/dn)An{dn(Bn −B)}+ cn(An −A)B, where dn(Bn −B)
converges to a normal distribution, An converge in probability to A and cn/dn → 0. Thus the first
term is op(1). Then we have cn(AnBn −AB) = cn(An −A)B + op(1).
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Under the assumption of the boundedness of the first three derivatives of m(x, a) and f(x, a),
we can prove that E
{
A˜n(x;β)
}
= A˜(x;β) + O(h2x + h
2
a). Together with the law of large numbers,
we obtain that A˜n(x;β)
p
−→ A˜(x;β). Since A˜n(x;β) is the sum of n i.i.d variables, with the central
limit theorem we can obtain that (nhqxh3a)
1/2{A˜n(x;β)− A˜(x;β)} converges to a normal distribution
if nhqxh3aVar{A˜n(x;β)} converges to a constant covariance matrix. Notice now that,
Var
{
A˜n(x;β)
}
=
1
n
Var
[
Yi
1
hqx
Kq(
x−Xi
hx
)
1
h2a
K˙
{g(βTx)−Ai
ha
}
g˙(βTx)x
]
=
1
n
g˙2(βTx)xxT
{
E
[
Y 2i
1
h2qx
Kq
2
(x−Xi
hx
) 1
h4a
K˙2
{g(βTx)−Ai
ha
}]
− E2
[
A˜n(x;β)
]}
=
1
n
g˙2(βTx)xxTE
[
Y 2i
1
h2qx
Kq
2(
x−Xi
hx
)
1
h4a
K˙2
{g(βTx)−Ai
ha
}]
+O(
1
n
),
where the expectation in the last equation can be calculated similarly as before:
E
[
Y 2i
1
h2qx
Kq
2(
x−Xi
hx
)
1
h4a
K˙2
{g(βTx)−Ai
ha
}]
=
1
hqxh3a
[
m2
{
x, g(βT x)
}
fX,A
{
x, g(βT x)
}
κ0,2κ˙0,2 +O(h
2
x) +O(h
2
a) +O(hxha)
]
.
Thus,
nhqxh
3
aVar
{
A˜n(x;β)
}
= g˙2(βTx)xxTm2
{
x, g(βTx)
}
fX,A
{
x, g(βT x)
}
κ0,2κ˙0,2 +O(h
q
xh
3
a).
Therefore, for nhqxh3a →∞ as n→∞, we have:
(nhqxh
3
a)
1/2
{
A˜n(x;β) − A˜(x;β)
}
→
N
[
0, g2(βTx)xxTm2
{
x, g(βTx)
}
fX,A
{
x, g(βT x)
}
κ0,2κ˙0,2
]
in distribution as n→∞.
Similarly, we can obtain that, as n→∞,
(nhqxh
3
a)
1/2
{
B˜n(x;β) − B˜(x;β)
} d
−→ N
[
0, g˙2(βTx)xxT fX,A
{
x, g(βTx)
}
κ0,2κ˙0,2
]
,
(nhqxh
3
a)
1/2
{
An(x;β) −A(x;β)
} d
−→ N
[
0,m2
{
x, g(βTx)
}
fX,A
{
x, g(βT x)
}
κ0,2κ˜0,2
]
,
(nhqxh
3
a)
1/2
{
Bn(x;β)−B(x;β)
} d
−→ N
[
0, fX,A
{
x, g(βT x)
}
κ0,2κ˜0,2
]
,
where κ˜0,2 =
∫
K2(s)ds.
By Lemma 3 and the above convergence results, we obtain that:
(nhqxh
3
a)
1/2
{
A˜n(x;β)Bn(x;β)− B˜n(x;β)An(x;β)
}
= (nhqxh
3
a)
1/2
{
A˜n(x;β)B(x;β) − B˜n(x;β)A(x;β)
}
+ op(1)
= (nhqxh
3
a)
1/2
{ 1
n
n∑
i=1
Φi(x;β)
}
+ op(1),
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where
Φi(x;β) =
{
YiB(x;β)−A(x;β)
} 1
hqx
Kq(
x−Xi
hx
)
1
h2a
K˙
{g(βTx)−Ai
ha
}
g˙(βTx)x.
Similar to previous calculations, by the central limit theorem we can prove that
(nhqxh3a)
1/2 {
∑n
i=1Φi(x;β)/n} converge to a normal distribution, where the covariance of the asymp-
totic distribution is ΣΦ(x;β):
ΣΦ(x;β) = g˙
2(βTx)xxTκ0,2κ˙0,2
[
m2
{
x, g(x′β)
}
−m2
{
x, g(x′β)
}]
f3X,A
{
x, g(x′β)
}
.
Notice that
(nhqxh
3
a)
1/2Gn(x;β) = (nh
q
xh
3
a)
1/2
{ 1
n
n∑
i=1
Φi(x;β)
} Cn(x)
B2n(x;β)
+ op(1).
Together with Cn(x)
p
−→ C(x), Bn(x;β)
p
−→ B(x;β), and Slusky’s theorem, we now obtain that:
(nhqxh
3
a)
1/2{Gn(x;β)−G(x;β)} → N
{
0,ΣG(x;β)
}
,
where:
ΣG(x;β) = g˙
2(βTx)xxTκ0,2κ˙0,2f
2
X(x)
m2
{
x, g(x′β)
}
−m2
{
x, g(x′β)
}
fX,A
{
x, g(x′β)
} .
Now let us calculate the covariance of Sn(x;β). By the tightness of Gn(x;β) and G(x;β),
(nhqxh3a)
1/2{Gn(x;β) − G(x;β)} converges weakly to a Gaussian process G(x)with mean 0 and co-
variance function ΣG(β), where ΣG(x1, x2;β) is the limit of
Cov
{
(nhqxh
3
a)
1/2Gn(x1;β), (nh
q
xh
3
a)
1/2Gn(x2;β)
}
=
hqxh3a
n
n∑
i=1
n∑
j=1
Cov
{
Φi(x1;β),Φj(x2;β)
} C(x1)C(x2)
B2(x1;β)B2(x2;β)
+ op(1)
=
hqxh3a
n
n∑
i=1
Cov
{
Φi(x1;β),Φi(x2;β)
} C(x1)C(x2)
B2(x1;β)B2(x2;β)
+ op(1)
= hqxh
3
aCov
{
Φ1(x1;β),Φ1(x2;β)
} C(x1)C(x2)
B2(x1;β)B2(x2;β)
+ op(1)
= T (x1, x2;β)
{ ∫
u
Kq(u)Kq(u+
x2 − x1
hx
)du
}[ ∫
v
K˙(v)K˙
{
v +
g(βTx1)− g(β
Tx2)
ha
}
dv
]
+ op(1),
for x1, x2 ∈ X , where
T (x1, x2;β) =[
m2
{
x1, g(β
T x1)
}
B(x1;β)B(x2;β)−m
{
x1, g(β
T x1)
}{
A(x2;β)B(x1;β)+
A(x1;β)B(x2;β)
}
+A(x1;β)A(x2;β)
]
g˙(βTx1)g˙(β
Tx2)x1x
T
2
C(x1)C(x2)
B2(x1;β)B2(x2;β)
.
When x1 6= x2,
∫
uKq(u)K{u+ (x2 − x1)/hx}du and
∫
v K˙(v)K˙ [v+ {g(β
T x1)− g(β
Tx2)} /ha]dv
will converge to 0 as hx, ha → 0. Thus ΣG(x1, x2;β) = 0 for x1 6= x2. Therefore,
(nhqxh
3
a)
1/2
{
Sn(β
∗)− S(β∗)
}
=
∫
x
(nhqxh
3
a)
1/2
{
Gn(x;β
∗)−G(x;β∗)
}
dx→ N
{
0,ΣS(β
∗)
}
,
in distribution, where ΣS(β) =
∫
x1
∫
x2
ΣG(x1, x2;β)dx1dx2 =
∫
xΣG(x;β)dx.
20
B.1.1 Proof of Equation (3)
First, write Dn(β) as:
Dn(β) =
∂2
∂β∂βT
Mn(β)
=
∫
x
{ ∂2
∂β∂βT
An(x;β)
Bn(x;β)
− 2
∂
∂βAn(x;β)
∂
∂βBn(x;β)
B2n(x;β)
−
An(x;β)
∂2
∂β∂βT
Bn(x;β)
Bn(x;β)2
+ 2
An(x;β)
∂
∂βBn(x;β)
∂
∂βT
Bn(x;β)
Bn(x;β)3
}
Cn(x)dx.
Similar to previous calculations, under the assumption of boundedness of the first three order
derivatives of m(x, a) and fX,A(x, a), we obtain that ∂
2An(x;β)/(∂β∂β
T ) converges in probability
to:
2
[
maa
{
x, g(βT x)
}
fX,A
(
x, g(βT x)
)
+ma
{
x, g(βT x)
}
fa
{
x, g(βT x)
}
+
m
{
x, g(βTx)
}
faa
{
x, g(βT x)
}]
g˙2(βTx)xxT
+
[
ma
{
x; g(βT x)
}
fX,A
{
x; g(βTx)
}
+m
{
x, g(βTx)
}
fa
{
x; g(βTx)
}]
g¨(βTx)xxT ,
and ∂2Bn(x;β)/(∂β∂β
T ) converges in probability to
2faa
{
x, g(βT x)
}
g˙2(βTx)xxT + fa
{
x, g(βT x)
}
g¨(βTx)xxT .
Together with the previous convergence results for A˜n(x;β), B˜n(x;β), An(x;β), Bn(x;β), Cn(x),
we obtain that Dn(β) converge in probability to∫
x
[
maa
{
x, g(βTx)
}
g˙2(βTx) +ma
{
x, g(βT x)
}
g¨(βTx)
]
fX(x)xx
Tdx = D(β).
B.1.2 Proof of Equation (4)
For notation, let xl be the l th component of the vector x, and βj and βk are the j th and k th
component of vector β, j, k, l ∈ {1, ...d}. Let Sn,l(β) be the l th component of vector Sn(β). Since
we have proved that βˆn − β
∗ converge in probability to 0, to prove Equation (4) it suffices to show
that: ∂2Sn,l(β)/(∂β∂β
T ) = Op(1), By calculation, for j, k, l ∈ {1, ..., d}:
∂2
∂βj∂βk
Sn,l(β)
=
∫
x
{ ∂2
∂βj∂βk
A˜n,l(x;β)
Bn(x;β)
− 3
B˜n,k(x;β)
∂
∂βj
A˜n,l(x;β)
B2n(x;β)
− 3
A˜n,l(x;β)
∂
∂βk
B˜n,j(x;β)
B2n(x;β)
−
An(x;β)
∂2
∂βj∂βk
B˜n,l(x;β)
B2n
+ 6
A˜n,l(x;β)B˜n,j(x;β)B˜n,k(x;β)
B3n
+ 2
An(x;β)
( ∂B˜n,l
∂βk
B˜n,j +
∂B˜n,j
∂βk
B˜n,l +
∂B˜n,l
∂βj
B˜n,k
)
B3n
− 6
An(x;β)B˜n,l(x;β)B˜n,j(x;β)B˜n,k(x;β)
B4n(x;β)
}
Cn(x)dx,
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where A˜n,j(x;β) is the j th component of vector A˜n(x;β) and B˜n,j(x;β) is the j th component of
vector B˜n(x;β). With similar calculation as before, under the assumption that the first four orders
of derivatives of m(x, a) and fX,A(x, a) are bounded, we obtain that: ∂
2Sn,l(β)/(∂βj∂βk) = Op(1).
Thus ∂2Sn,l(β)/(∂β∂β
T ) = Op(1).
C Estimation of Covariance
From above, the covariance of the asymptotic distribution for (nhqxh3a)
1/2(βˆn − β
∗) is given by:
D(β∗)−1ΣS(β
∗)D(β∗)−1.
First, D(β) can be estimated with Dn(β). Then for the estimation of ΣS(β), notice that ΣS(β) =∫
x1
∫
x2
ΣG(x1, x2;β)dx1dx2 =
∫
xΣG(x;β)dx, and
(nhqxh
3
a)
1/2Gn(x;β) = (nh
q
xh
3
a)
1/2
{ 1
n
n∑
i=1
Φi(x;β)
} Cn(x)
B2n(x;β)
+ op(1).
Therefore, ΣG(x;β) = ΣΦ(x;β)C
2
n(x)/B
4
n(x;β) where ΣΦ(x;β) can be estimated empirically by the
sample covariance of Φi(x;β). Φi(x;β) is approximated by plugging in the An(x;β), Bn(x;β), Cn(x)
for A(x;β), B(x;β) and C(x). Finally, we plug in βˆn for β
∗ to obtain the estimated covariance.
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